8
Clinical Trials associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)Prospective, Multicenter, Open, One-arm Clinical Study of Safety and Efficacy of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.
/ RecruitingEarly Phase 1IIT Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus autogolous hematopoietic stem cell transplantation for non-complete remission multiple myeloma: a single center, open-label, randomized controlled trial
Start Date01 Nov 2019 |
Sponsor / Collaborator- |
/ RecruitingEarly Phase 1IIT Combination of humanized anti-CD19 CAR-T and anti-BCMA CAR-T versus anti-BCMA CAR-T alone for relapsed or refractory multiple myeloma:a multicenter, open-label, randomized controlled trial
100 Clinical Results associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Translational Medicine associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Patents (Medical) associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)
100 Deals associated with Anti-CD19 CAR-T (The Affiliated Hospital of Xuzhou Medical University)